ES2365258T3 - Derivados de tiazol condensados como inhibidores de quinasa. - Google Patents

Derivados de tiazol condensados como inhibidores de quinasa. Download PDF

Info

Publication number
ES2365258T3
ES2365258T3 ES07733382T ES07733382T ES2365258T3 ES 2365258 T3 ES2365258 T3 ES 2365258T3 ES 07733382 T ES07733382 T ES 07733382T ES 07733382 T ES07733382 T ES 07733382T ES 2365258 T3 ES2365258 T3 ES 2365258T3
Authority
ES
Spain
Prior art keywords
alkyl
amino
dialkyl
pyrazolyl
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07733382T
Other languages
English (en)
Spanish (es)
Inventor
Rikki Peter Alexander
Pavandeep Singh Aujla
Karen Viviane Lucile CRÉPY
Anne Marie Foley
Richard Jeremy Franklin
Alan Findlay Haughan
Helen Tracey Horsley
William Mark Jones
Bénédicte Irma Léonce Frédérique LALLEMAND
Stephen Robert Mack
Trevor Morgan
Patrick Marie Ghislain Pasau
David Jonathan Phillips
Verity Margaret Sabin
George Martin Buckley
Kerry Jenkins
Benjamin Garfield Perry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Application filed by UCB SA filed Critical UCB SA
Application granted granted Critical
Publication of ES2365258T3 publication Critical patent/ES2365258T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES07733382T 2006-06-26 2007-06-26 Derivados de tiazol condensados como inhibidores de quinasa. Active ES2365258T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0612644 2006-06-26
GB0620062 2006-10-10
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2365258T3 true ES2365258T3 (es) 2011-09-27

Family

ID=38671000

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07733382T Active ES2365258T3 (es) 2006-06-26 2007-06-26 Derivados de tiazol condensados como inhibidores de quinasa.
ES08775774T Active ES2416364T3 (es) 2006-06-26 2008-06-24 Derivados de tiazol condensados como inhibidores de cinasas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08775774T Active ES2416364T3 (es) 2006-06-26 2008-06-24 Derivados de tiazol condensados como inhibidores de cinasas

Country Status (20)

Country Link
US (3) US8242116B2 (cg-RX-API-DMAC10.html)
EP (2) EP2035436B1 (cg-RX-API-DMAC10.html)
CN (1) CN101687885B (cg-RX-API-DMAC10.html)
AT (1) ATE510840T1 (cg-RX-API-DMAC10.html)
AU (1) AU2008269577B2 (cg-RX-API-DMAC10.html)
CA (1) CA2692085C (cg-RX-API-DMAC10.html)
CO (1) CO6270229A2 (cg-RX-API-DMAC10.html)
CY (1) CY1114419T1 (cg-RX-API-DMAC10.html)
DK (1) DK2170906T3 (cg-RX-API-DMAC10.html)
EA (1) EA017187B1 (cg-RX-API-DMAC10.html)
ES (2) ES2365258T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20130523T1 (cg-RX-API-DMAC10.html)
IL (1) IL202659A0 (cg-RX-API-DMAC10.html)
ME (1) ME01592B (cg-RX-API-DMAC10.html)
MX (1) MX2009013740A (cg-RX-API-DMAC10.html)
MY (1) MY148852A (cg-RX-API-DMAC10.html)
PL (1) PL2170906T3 (cg-RX-API-DMAC10.html)
PT (1) PT2170906E (cg-RX-API-DMAC10.html)
RS (1) RS52824B (cg-RX-API-DMAC10.html)
WO (1) WO2008001076A1 (cg-RX-API-DMAC10.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
ATE531372T1 (de) 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
US8603945B2 (en) * 2008-07-23 2013-12-10 The Regents Of The University Of California Methods and compositions for providing salicyclic acid-independent pathogen resistance in plants
EP2341052A4 (en) * 2008-09-05 2011-10-12 Shionogi & Co RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
AU2010216219A1 (en) 2009-02-17 2011-09-01 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
AR076126A1 (es) * 2009-03-18 2011-05-18 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
ES2638323T3 (es) * 2009-05-20 2017-10-19 Glaxosmithkline Llc Derivados de tiazolopirimidinona como inhibidores de PI3 quinasa
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
MX2012002059A (es) 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
EA020010B1 (ru) * 2009-12-18 2014-07-30 Янссен Фармацевтика Нв БИЦИКЛИЧЕСКИЕ ТИАЗОЛЫ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 РЕЦЕПТОРОВ
ES2431302T3 (es) 2009-12-18 2013-11-25 Janssen Pharmaceutica, N.V. Tiazoles bicíclicos como moduladores alostéricos de receptores mGluR5
EP2582693B1 (de) 2010-06-15 2016-03-30 Bayer Intellectual Property GmbH Neue ortho-substituierte arylamid-derivate
BR112013007056A2 (pt) 2010-10-01 2019-09-24 Basf Se compostos de imina
AU2011316016A1 (en) * 2010-10-13 2013-05-30 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
BR112013012961A2 (pt) * 2010-11-24 2019-09-24 Exelixis Inc benzoxazepinas como inhibidores de mtor e métodos de seu uso e fabricação
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970220A2 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
BR112015022785A2 (pt) 2013-03-14 2017-07-18 Epizyme Inc composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
CA2903264A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2015059049A1 (de) * 2013-10-21 2015-04-30 Umicore Ag & Co. Kg Monoarylierung aromatischer amine
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
US20220202824A1 (en) 2018-09-13 2022-06-30 Stemline Therapeutics, Inc. Methods for Treating Centronuclear Myopathy
AU2019410261B2 (en) 2018-12-19 2025-10-02 Leo Pharma A/S Amino-acid anilides as small molecule modulators of IL-17
BR112021013105A2 (pt) * 2019-01-08 2021-09-21 Kyorin Pharmaceutical Co., Ltd. Inibidor de 15-pgdh
JP7532385B2 (ja) 2019-01-31 2024-08-13 杏林製薬株式会社 15-pgdh阻害薬

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508471D0 (en) 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents

Also Published As

Publication number Publication date
AU2008269577B2 (en) 2012-12-20
ATE510840T1 (de) 2011-06-15
CO6270229A2 (es) 2011-04-20
EA201000038A1 (ru) 2010-06-30
US8338592B2 (en) 2012-12-25
AU2008269577A1 (en) 2008-12-31
MY148852A (en) 2013-06-14
ME01592B (me) 2014-09-20
ES2416364T3 (es) 2013-07-31
EP2170906B1 (en) 2013-04-03
US20130079330A1 (en) 2013-03-28
PL2170906T3 (pl) 2013-08-30
US8710054B2 (en) 2014-04-29
EA017187B1 (ru) 2012-10-30
EP2035436A1 (en) 2009-03-18
IL202659A0 (en) 2010-06-30
CA2692085A1 (en) 2008-12-31
EP2035436B1 (en) 2011-05-25
CN101687885A (zh) 2010-03-31
PT2170906E (pt) 2013-06-25
US8242116B2 (en) 2012-08-14
US20110003785A1 (en) 2011-01-06
CA2692085C (en) 2015-10-13
DK2170906T3 (da) 2013-06-24
HRP20130523T1 (en) 2013-07-31
MX2009013740A (es) 2010-02-01
EP2170906A1 (en) 2010-04-07
CY1114419T1 (el) 2016-08-31
US20100137302A1 (en) 2010-06-03
RS52824B (cg-RX-API-DMAC10.html) 2013-10-31
CN101687885B (zh) 2012-08-22
WO2008001076A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
ES2365258T3 (es) Derivados de tiazol condensados como inhibidores de quinasa.
US8217176B2 (en) Fused heterocyclic derivative and use thereof
ES2505270T3 (es) Inhibidores de JAK2 y su uso para el tratamiento de enfermedades mieloproliferativas y cáncer
AU2017228385B2 (en) Substituted indole Mcl-1 inhibitors
AU2007231577B2 (en) c-MET protein kinase inhibitors for the treatment of proliferative disorders
US9714248B2 (en) Therapeutically active pyrazolo-pyrimidine derivatives
ES2372540T3 (es) Activadores de glucocinasa.
MD3448859T2 (ro) Compoziții de pirolopirol în calitate de activatori ai piruvatkinazei (PKR)
CA2925624A1 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
KR20130049766A (ko) 트리사이클릭 피라졸 아민 유도체
BRPI0709171A2 (pt) ativadores de glicoquinase, composição, usos dos referidos ativadores e métodos para preparação dos mesmos
EP2471791B1 (en) Fused heterocyclic ring derivative and use thereof
EP2776445A1 (en) Therapeutically active thiazolo-pyrimidine derivatives
WO2009071895A1 (en) Fused thiazole and thiophene derivatives as kinase inhibitors
US8168634B2 (en) Thiazole derivatives as kinase inhibitors
US8093238B2 (en) Fused thiazole derivatives as kinase inhibitors
KR101577314B1 (ko) 키나제 억제제로서의 접합된 티아졸 유도체
USRE48622E1 (en) Therapeutically active pyrazolo-pyrimidine derivatives
WO2010146351A1 (en) Indolylmethyl-morpholine derivatives as kinase inhibitors
ES2822586T3 (es) Inhibidores de btk de tipo nicotinimida sustituida y su preparación y uso en el tratamiento del cáncer, la inflamación y las enfermedades autoinmunitarias